SER-AP-ES Drug Patent Profile
✉ Email this page to a colleague
When do Ser-ap-es patents expire, and what generic alternatives are available?
Ser-ap-es is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in SER-AP-ES is hydralazine hydrochloride; hydrochlorothiazide; reserpine. There are twenty-one drug master file entries for this compound. Additional details are available on the hydralazine hydrochloride; hydrochlorothiazide; reserpine profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SER-AP-ES?
- What are the global sales for SER-AP-ES?
- What is Average Wholesale Price for SER-AP-ES?
Summary for SER-AP-ES
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 133 |
| DailyMed Link: | SER-AP-ES at DailyMed |
US Patents and Regulatory Information for SER-AP-ES
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | SER-AP-ES | hydralazine hydrochloride; hydrochlorothiazide; reserpine | TABLET;ORAL | 012193-005 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
